The advances in neuroimaging in the last decades have bridged the translational gap and enabled our understanding of the brain under different physiological and disease conditions. In animal models of Alzheimer’s disease, multiscale and multimodal imaging (e.g., positron emission tomography, magnetic resonance imaging, and optical imaging) have enabled non-invasive visualization of the neuropathology (amyloid-beta and tauopathy), neurodegeneration, and functional alterations. We recently developed novel optoacoustic tomography (resolution 100 um) and fluorescence microscopy (resolution 6 um) imaging methods that enable whole-brain non-invasive transcranial detection of amyloid-beta/tau at high spatial resolution. These platforms offer new prospects for in vivo studies into Alzheimer’s disease mechanisms in animal models and longitudinal monitoring of therapeutic responses targeting amyloid-beta deposits and tau neurofibrillary tangles. Currently, we are developing imaging tools for detecting alpha-synuclein inclusions in mouse models of Parkinson’s disease.
Subject Matter Level:
• Intermediate - Assumes basic knowledge of the topic
What You Will Learn in the Webinar:
• Use of noninvasive, multimodal optical imaging for studying Alzheimer’s disease and Parkinson's disease in animal models
Who Should Attend:
• Scientists, researchers, and professors
• Postdoctoral fellows
• Graduate and undergraduate students
• All of the above in the fields of biomedical engineering, biophotonics, optical imaging, and neuroscience.